- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patient Specific Factors: Guiding Treatment in Bronchiectasis
Pamela J. McShane, MD, explains her approach to diagnosing the underlying cause of bronchiectasis, which includes identifying cystic fibrosis in older patients, and emphasizes the importance of helping patients lead a normal life while managing their condition.
EP: 1.Overview of Bronchiectasis
EP: 2.Prognosis For Patients Diagnosed With Bronchiectasis
EP: 3.Indicators Leading to Bronchiectasis Testing and Diagnosis
EP: 4.Complications Associated With Bronchiectasis
EP: 5.Current Treatment Options For Bronchiectasis
EP: 6.Respiratory and Physical Therapists Contributing to Comprehensive Bronchiectasis Care
EP: 7.Key Areas of Research and Emerging Therapies In Bronchiectasis Treatment
EP: 8.Diagnosing and Understanding the Pathogenesis of Bronchiectasis
EP: 9.Improving Long-Term Outlook: CT Scans and Underdiagnosis of Bronchiectasis
EP: 10.Bronchiectasis Exacerbation Management
EP: 11.Social Burden and Goals of Therapy for Patients with Bronchiectasis
EP: 12.Patient Specific Factors: Guiding Treatment in Bronchiectasis
EP: 13.Individualized Therapy for Specific Infections Associated with Bronchiectasis
EP: 14.Other Challenges With Bronchiectasis and Key Takeaways
EP: 15.Identifying Bronchiectasis: Key Clinical Presentations to Consider
EP: 16.Differentiating Bronchiectasis from COPD and Understanding Exacerbations
EP: 17.Long-Term Impact of Bronchiectasis Exacerbations: Disease Progression, Patient Outcomes, and Economic Burden
EP: 18.Managing Bronchiectasis: Treatment Goals, Outcome Measures, and Clinical Decision Resources
EP: 19.Addressing Knowledge Gaps and Treatment Strategies in Bronchiectasis
EP: 20.Challenges and Future Directions in Bronchiectasis Management
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More
